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Ageing is a complex process characterised by a variety of disorders associated with general organismal decline and an inability to
maintain tissue homoeostasis. As described in this review, recent studies indicate that ageing may be caused, in part, by the depletion
of stem and progenitor cells that govern tissue renewal. The potential causes of stem and progenitor cell attrition are numerous;
however, a commonly accepted theory is that these cells are lost as a result of naturally occurring DNA damage and the obligate
checkpoint responses that follow. Failure to launch appropriate responses to DNA damage is strongly associated with cancer
initiation and progression. Therefore, it is at this nexus, the response to DNA damage, that an important organismal fate may be
determined: to degrade regenerative potential for the purpose of preventing cancer. According to this viewpoint, ageing may be the
unfortunate mark of successful cancer suppression in stem cells and other cell types. In this review, we will describe how degeneration
of tissue renewal capacity links ageing and cancer suppression.
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Cancer and ageing are well correlated. That is, cancer risk
increases in a manner that is, generally speaking, coincident with
increasing age (Figure 1). Furthermore, both cancer and ageing
have been proposed to be attributable to a similar fundamental
cause: the accumulation of DNA damage (Hasty et al, 2003;
Lombard et al, 2005). Although cancer and age-related diseases are
well correlated, there is an exception; a statistically significant
decrease in cancer is observed in human populations beyond
85 years of age (Figure 1). This apparent decrease could be the
consequence of selection for those individuals that are devoid
of cancer-predisposing genes. However, an increasing body of
evidence supports a different hypothesis: that processes linked to
ageing, both cellular and organismal, may suppress cancer. This
theory taps into several converging lines of evidence. The first line
demonstrates that stem and progenitor cells rely on the induction
of tumour-suppressing genes, such as p16
INK4A and p53, to
suppress cell growth in the event of DNA damage or hyperactive
growth factor signalling. By inducing permanent cell cycle arrest
(senescence) or programmed cell death (apoptosis), these genes
suppress tumourigenesis, but may also consequently degrade stem
and progenitor cell pools. Therefore, over the long term, the
response to DNA damage and replicative stress may lead to
exhaustion of tissue renewal capacity. Another line of evidence
indicates that stem and progenitor cells exhaustion can contribute
substantially to the process of ageing, as determined by observa-
tions of stem and progenitor cells attrition in mouse models in
which genome maintenance is compromised. Together, these
studies indicate that hyperactive growth factor signalling and
accumulated DNA damage are the initial causes of a branching
chain of events that leads to ageing, when tumour-suppressive
mechanisms are effective, and cancer, when such mechanisms fail.
STEM CELL EXHAUSTION AND AGEING
Ageing is a complex process generally characterised by reduced
cellular function and an inability to maintain tissue homoeostasis.
Age-related changes include slowed wound-healing responses and
haematopoietic recovery rates, osteoporosis, kyphosis, hair loss
and graying, reduced fertility, muscle loss, neurodegeneration and
cancer (Hasty et al, 2003; Kipling et al, 2004; Lombard et al, 2005).
These phenotypes are not uniformly expressed in all individuals
and are not strictly age associated in all cases (eg alopecia);
however, the appearance of these phenotypes in general is strongly
correlated with advancing age. A number of human progeroid
syndromes (Werner, Cockayne, Hutchinson-Gilford, trichothyo-
dystrophy, dyskeratosis congenita, ataxia-telangiectasia) and
mutant mouse models (below) recapitulate some aspects of normal
ageing and in many instances produce extreme examples of these
disorders (Hasty et al, 2003; Kipling et al, 2004; Lombard et al,
2005). Predominantly, the genes mutated in these examples are
required for genome maintenance, either in the form of DNA
repair or in the cell cycle-regulatory response to DNA damage.
Therefore, increased genomic instability is sufficient to speed the
onset of age-related disorders. However, while DNA damage may
be a well-accepted root cause of ageing, how DNA damage causes
ageing at the organismal level is still unclear. As noted above,
decreased tissue maintenance and rates of regeneration provide a
unifying thread between many age-related phenotypes. Although
DNA damage affects many cell types, including terminally
differentiated cells, the depletion of stem and progenitor cell pools
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www.bjcancer.comwould be expected to cause a potent effect on regeneration of many
tissues (Van Zant and Liang, 2003; Rando, 2006). Recent evidence
using targeted deletions of important genome-maintenance
regulators in mice lends credence to the hypothesis that stem
and progenitor cell exhaustion leads to age-related phenotypes.
The age-associated disorders described above have been obser-
ved in a number of mouse models, although to varying degrees.
These models include Ku86
 / , XPD
R722W/R722W, BRCA1
D11/D11
p53
þ/ , XRCC4
 / p53
S18A/S23A, LIG4
Y288C, Rad50
S/S, Terc
 / ,
Wrn
 / Terc
 /  and those expressing putatively hypermorphic
variants of p53 (Hasty et al, 2003; Lombard et al, 2005; Chao et al,
2006). Tissue regenerative failures are observed in some form or
another in each of these models, and recent reports indicate that
mutation of many of these same genome-maintenance regulators
leads to decreased stem cell number and potential with age (Ito
et al, 2004; Nijnik et al, 2007; Rossi et al, 2007). In addition, recent
study of haematopoietic stem cells from aged normal mice
revealed a decline in stem cell regenerative potential and epigenetic
downregulation of genes involved in the maintenance of genomic
integrity (Chambers et al, 2007). Although mutant mouse models
may not fully reflect all of the events happening during normal
mammalian ageing, the observed correlations may help us
understand the mechanisms by which natural ageing can occur.
The specific cause of regenerative failures has been predomi-
nantly studied in mice in which Terc, a telomerase co-factor, has
been mutated. After three generations in the absence of telomerase
(G3), Terc
 /  mice are born with significantly shortened
telomeres, which causes chromosome end fusions and persistent
genomic instability through the bridge-breakage-fusion cycle
(Rudolph et al, 1999). At G3 and beyond Terc
 /  mice exhibit
impaired haematopoiesis, atrophy of the intestinal epithelium,
decreased spermatogenesis and reduced regenerative capacity in
response to wounds and haematopoietic ablation (Rudolph et al,
1999). Telomerase loss in combination with deletion of genes that
regulate alternative telomere lengthening, such as the gene
mutated in Werner and Bloom syndromes, accelerates telomere
shortening. These compound mutants have accentuated degen-
erative phenotypes, which appear at earlier generation times, and
suffer additional pathologies, such as bone loss and kyphosis
(Chang et al, 2004; Du et al, 2004). Importantly, stem cells, which
normally express telomerase, are particularly sensitive to telomer-
ase loss (Flores et al, 2006; Hiyama and Hiyama, 2007). Thus,
increased genomic instability from telomerase absence in haema-
topoietic stem cells (HSCs), spermatogonia and progenitor cells in
the intestinal crypts is likely to be the cause of homeostatic failure
in the bone marrow, testes and intestines, respectively (Rudolph
et al, 1999; Choudhury et al, 2007). Together, these data are
consistent with the notion that decreased genome maintenance in
stem and progenitor cells accelerates tissue degeneration with age.
Recent studies imply that stem cell attrition in Terc
 /  mice is
not so much the product of DNA damage itself, but rather of the
response to DNA damage. DNA damage leads to the activation of
checkpoint signalling pathways mediated by the ATM and Rad3
related (ATR) and Ataxia-telangiectasia mutated (ATM) protein
kinases, which, among other things, phosphorylate and stabilise
the p53 transcription factor (Kastan and Bartek, 2004). Activated
p53 consequentially stimulates the expression of cell cycle
regulators, such as p21, and, in some cell types, initiates cell death
programs via upregulation of pro-apoptotic genes. Importantly,
elimination of p21 largely rescues haematopoiesis and intestinal
villi generation in late generation Terc
 /  mice (Choudhury
et al, 2007). Moreover, p21 absence returns HSCs (CD34
lo/
 Lin
 Sca1
þc-Kit
hi) to normal numbers in G4 Terc
 /  mice and
dramatically enhances HSC potential for generating downstream
progenitors. The number and proliferative potential of intestinal
progenitors in Terc
 /  mice were also dramatically enhanced by
elimination of p21. Interestingly, these degenerative phenotypes
were lessened by p21 absence without rescuing either telomere
attrition or DNA damage, as measured by increased H2AX
phosphorylation (Choudhury et al, 2007). These data strongly
argue that the response to DNA damage, not DNA damage per se,
can cause a decrease in tissue renewal capacity.
It is important to point out that stem cells normally express
telomerase; therefore, they may not suffer telomere attrition during
normal ageing, in contrast to other cells. Besides telomere loss, DNA
damage occurs constitutively in all cell types as a by-product of
normal metabolic respiration and from unavoidable failures during
DNA replication. Thus, one model of ageing predicts that replicative
and oxidative stress in the course of stem cell proliferation leads to
slow stem cell attrition throughout adulthood, and this attrition
ultimately degrades tissue homoeostasis. One way to test such a
model would be to ablate the proliferative potential of a large
fraction of cells in young adult animal while leaving the remaining
fraction of cells relatively untouched. Taking a large fraction of cells
out of the proliferative pool early in life at one stroke should shorten
the length of time in which a particular stem cell compartment will
be able to continue to contribute to tissue renewal and, thus, would
accelerate ageing. Such a study has recently been performed by
deleting an essential genome-maintenance and checkpoint regula-
tor, ATR, in adult mice (Ruzankina et al,2 0 0 7 ) .
The ATR protein kinase senses problems during DNA replica-
tion and, in the event of stalled DNA replication, maintains
replication fork stability and prevents cell cycle progression.
Stalled DNA replication appears to be a common event during
normal cellular proliferation, since elimination of ATR in cultured
proliferating cells results in catastrophic loss of genome integrity,
cell cycle exit and apoptosis (Brown and Baltimore, 2000; Cortez
et al, 2001; Casper et al, 2002; Brown and Baltimore, 2003). While
ATR is essential for embryonic development (Brown and
Baltimore, 2000), mosaic deletion of ATR in adult mice (ATR
mKO)
via a tamoxifen-inducible form of Cre recombinase leads to the
rapid appearance of a number of age-related phenotypes including
hair graying, alopecia, kyphosis, osteoporosis, premature thymic
involution, loss of spermatogenesis and increased tissue fibrosis
(Ruzankina et al, 2007). Consistent with the importance of stem
cells in preventing age-related disease, thymic involution, alopecia
and hair graying in ATR
mKO mice were associated with dramatic
reductions in tissue-specific stem and progenitor cells and
exhaustion of tissue renewal and homeostatic capacity.
Importantly, the phenotypes observed in ATR
mKO mice do not
appear to be caused by the persistence of ATR mutant cells.
Following Cre recombination, ATR knockout cells were rapidly
depleted from affected tissues. This depletion was attributable to
the proliferative failure of ATR knockout cells, which is most likely
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Cancer incidence by age group
Figure 1 Cancer incidence increases with age; however, there is a
significant decrease in cancer incidence after the age of 85. Cancer
incidence by age group based on Cancer Registry Public Information Data:
1999–2002, WONDER Online Database, United States Department of
Health and Human Services (http://wonder.cdc.gov/).
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(Brown and Baltimore, 2003; Ruzankina et al, 2007). Concomitant
with the depletion of ATR-deleted cells, most of these same
tissues were rapidly reconstituted with the small percentage of
ATR-expressing cells that escaped lox recombination. Therefore,
the long-term failure of stem and progenitor cells in ATR
mKO mice
took place despite ample reconstitution with ATR-expressing cells.
These results suggest that elimination of ATR knockout cells leads
to the proliferative exhaustion of the remaining ATR-expressing
cells, which in turn causes degeneration of tissue renewal capacity
(Krishnamurthy and Sharpless, 2007; Ruzankina et al, 2007).
Many questions remain to be answered using these mouse
models and others. For examples, it is possible that ATR deletion
also affects the niches that maintain stem cells; thus, ATR-
expressing stem cell pools may be depleted by both cell intrinsic
and extrinsic mechanisms. Intrinsic HSC defects and niche
degeneration have each been observed in telomerase-deficient
mice (Choudhury et al, 2007; Ju et al, 2007). In addition, while
telomerase deficiency causes a relatively slow, but persistent,
accumulation of DNA damage, ATR elimination leads to an
immediate catastrophic loss of genome integrity and clearance of
the damaged cells (Ruzankina et al, 2007). At present, it is not clear
to what extent the DNA damage response plays a role in the onset
of age-related phenotypes in ATR
mKO mice and if p53 and p21
deficiency may rescue the appearance of these phenotypes.
These data indicate that the loss of stem cell function as a result
of DNA damage correlates with and may be sufficient to cause at
least some aspects of normal ageing. In particular, it appears that
the response to DNA damage, not DNA damage per se, may cause
the loss of regenerative capacity. At first appearance, the advantage
of preventing tissue renewal on an organismal level is not clear,
until another effect of DNA damage is considered.
TUMOUR-SUPPRESSING MECHANSIMS DEGRADE
TISSUE RENEWAL CAPACITY
As described above, stem cells and their downstream progeny
are subjected to DNA damage from a broad range of sources
including the by-products of normal metabolic respiration and
unavoidable failures during DNA replication. In addition, hyper-
active proliferative signalling via proto-oncogene expression
and activation (eg Bmi1, Wnt, b-catenin, Shh) are also a normal
part of cell renewal and have been shown to be keenly important
for stem cell maintenance (Pardal et al, 2005). Both DNA damage
and uncontrolled proliferative signalling are key elements to
cancer initiation and progression. Therefore, because DNA damage
and hyperactive proliferative signalling are unavoidable conse-
quences of living, the senescence and apoptotic programs initiated
by these stimuli are essential barriers to tumourigenesis in
multicellular organisms.
Two of the best characterised regulators of senescence and
apoptosis in response to DNA damage and proto-oncogneic
signalling are p16
INK4A and p53. Each is induced by DNA damage
and oncogenic stress and has been shown to suppress cancer in
mouse models. Disruption of p16
INK4A in mice leads to increased
risk of osteosarcomas, histiocytic lymphomas and melanomas and
inactivation of INK4A in humans is found in approximately 30%
of the most common cancers (Kim and Sharpless, 2006). A similar
high correlation between p53 loss and increased cancer incidence
has been observed in humans and p53 mutant mice (Kastan
and Bartek, 2004). The importance p16
INK4A and p53 in tumour
suppression in the absence of abnormal environmental factors
indicates that these genes are utilised frequently throughout life
and that cancer incidence is indicative of their failure.
Because activation of p16
INK4A and p53 affects continued cellular
proliferation through either senescence or apoptosis, the
constant activation of p16
INK4A and p53 could influence long-term
tissue homoeostasis. Accumulation of senescent cells has long been
viewed as potential cause of ageing (Campisi, 2005), and it has
been shown that abnormally high levels of apoptosis achieved by
genetically altering mitochondrial function leads to the premature
appearance of age-related phenotypes (Kujoth et al, 2005). As
described below, recent evidence supports the hypothesis that
effective cancer suppression ultimately degrades tissue renewal
capacity. According to this model, one would expect that
hyperactivation of tumour-suppressing pathways in the absence
of increased DNA damage or proto-oncogenic signalling would be
sufficient to cause aspects of ageing. In contrast, loss of tumour-
suppressing pathways may slow tissue degeneration. Each of these
expectations has been at least partly fulfilled by the generation and
analysis of mouse models that alter the activity and/or expression
of p53 and p16
INK4A.
In one mouse model, a serendipitous deletion in p53 (p53
m) was
generated in the course of conventional gene targeting, leading to a
putative 24kDa N-terminally truncated protein (Tyner et al, 2002).
In the background of a p53 null allele (p53
m/ ), p53
m appears to be
non-functional; however, when in the presence of a wild-type copy
of p53 (p53
þ/m), the p53
m allele causes a small but detectable
hypermorphic effect on the transcription of p53 target genes and
suppression of oncogene-mediated transformation in culture.
Presumably, the effect of the 24kDa protein is mediated through
higher order complex formation with wild-type p53 in p53
þ/m mice.
p53 hyperactivation in these mice is accompanied by a B20%
shorter median lifespan and the premature appearance of several
age-related phenotypes, including osteoporosis, kyphosis, general-
ised organ atrophy, impaired wound healing, hair re-growth
defects and slowed recovery following myeloablation. While it has
been shown that the deletion leading to this truncation also causes
haploinsufficient loss of 23 nearby genes (Gentry and Venkata-
chalam, 2005), a careful analysis of the phenotypes observed in
p53
þ/m, p53
m/  p53
þ/  and p53
 /  mice suggests that the
premature ageing phenotypes in p53
þ/m mice are most likely
related to the p53 truncation (Vijg and Hasty, 2005). In addition,
phenotypes consistent with those observed in p53
þ/m mice have
been obtained by expressing a naturally occurring N-terminally
truncated isoform of p53 called p44 (Maier et al, 2004). Transgenic
p44 mice manifest several aspects of premature ageing as well as a
significantly reduced lifespan (32 week median). Consistent with
the hypothesis that p53 activity suppresses cancer initiation and
progression, p53
þ/m mice exhibit decreased cancer incidence (6%)
in comparison to wild-type control mice (45%), although this
incidence may be underrepresented due to decreased longevity
(Tyner et al, 2002). Importantly, a recent report by the same group
has gone on to show that the p53
þ/m mice have reduced HSC
number and proliferative potential and that p53 haploinsufficiency
(p53
þ/ ) appears to lead to increased HSC number and potential
in late age mice (Dumble et al, 2007). These studies indicate that
aberrant hyperactivation of the p53 pathway can cause the
premature appearance of age-related phenotypes.
It is important to note that, in contrast to aberrant p53
hyperactivation, an additional copy of p53 under normal regulatory
control (super-p53 mice) and reduced expression of the p53
inhibitor Mdm2 do not accelerate ageing (Garcia-Cao et al,2 0 0 2 ;
Mendrysa et al, 2006). Furthermore, the super-p53 transgene in
combination with an extra copy of the Arf locus (super-p53/super-
Arf) protects mice against oxidative DNA damage and cancer and
extends lifespan (Matheu et al,2 0 0 7 ) .I ti sc o n c e i v a b l et h a ti n c r e a s e d
quantities of p53 under normal regulatory control can enhance the
clearance and suppress the accumulation of mutant cells without
causing the wholesale loss of all cell types, such as has been proposed
to occur from aberrant regulation of p53 (p53
þ/m). Together, these
studies indicate that the cause and level of p53 activation strongly
influence the development of age-related phenotypes.
Like p53, INK4A is upregulated in response to oncogenic stress
and DNA damage, although with kinetics that differ from p53. The
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the p53-p21 transcriptional axis; however, once these factors wane,
p16
INK4A levels begin to rise to cause irretrievable cell cycle exit
through senescence (Campisi, 2005; Kim and Sharpless, 2006). In
accord with 16
INK4A-mediated senescence playing an important
role in ageing, 16
INK4A has been shown to be upregulated in
various tissues in aged humans and rodents, and overexpression of
p16
INK4A in mice to a degree observed with ageing leads to
decreased b-islet regeneration (Krishnamurthy et al, 2004;
Krishnamurthy et al, 2006; Ressler et al,2 0 0 6 ) .I fp 1 6
INK4A upregu-
lation is a cause of age-associated loss of regenerative capacity, then
one would expect that deletion of p16
INK4A would suppress stem
and progenitor cell attrition and tissue degeneration with age. For
some tissues, this expectation has been fulfilled, at least in part.
Age-related decline in proliferation of the forebrain progenitors,
pancreatic b-islet cells and HSCs were rescued significantly upon
deletion of p16
INK4A in mice, as were regeneration of the corres-
ponding tissues (Janzen et al, 2006; Krishnamurthy et al, 2006;
Molofsky et al, 2006). These studies strongly indicate that naturally
occurring upregulation of p16
INK4A levels with age form a rate-
limiting block in tissue regeneration and that deletion of p16
INK4A
alone is sufficient to remove at least part of this blockade.
Importantly, age-related attrition was not rescued in all stem and
progenitor cell types in which p16
INK4A was deleted, indicating that
reduced proliferative potential of some cell types with age does not
rely on p16
INK4A (Molofsky et al, 2006) and that other rate-limiting
factors may be involved. In aggregate, these studies imply that the
activation of senescent and apoptotic signalling pathways, putatively
resulting from unavoidable DNA damage and proto-oncogenic
stress, can lead to reduced tissue regenerative capacity with age.
DOES AGEING SUPPRESS CANCER?
While cancer and ageing are generally correlated, it may be that
this relationship is simply rooted in common events, for example,
DNA damage and proto-oncogenic signalling. According to the
viewpoint described herein, it may be the effectiveness of the
response to these events that determines the diametrically opposite
outcomes of decreased tissue regeneration and tumourigenesis
(Figure 2). If tumour-suppressing mechanisms, such as apoptosis
and senescence, have been overly effective throughout life, then the
consequential decrease in regeneration rates might also decrease
the total output of newly generated cells that can progress to
cancer. Thus, the small but statistically significant decline in cancer
incidence in late ageing individuals may be the product of
decreased regenerative rates and stem cell numbers. While reports
in support of this hypothesis are scattered, two examples discussed
herein are p53
þ/m and ATR
mKO mice, which have reduced
regenerative potential and appear to have a decreased tumour risk
in comparison to controls (Tyner et al, 2002; Ruzankina et al,
2007). It is also possible that loss of stem and progenitor cells
themselves may decrease the pool of cells available for transforma-
tion, according to the hypothesis that some cancers are derived
directly from these cell types (Ward and Dirks, 2007). For example,
mice disrupted for CD34, a marker of hair follicle bulge stem cells,
display a significant delay in follicle cycling and, in contrast to
wild-type mice, do not develop skin papillomas in response to 7,12-
dimethylbenz(a)anthracene (DMBA) and 12-O-tetradecanoylphorbol-
13-acetate (TPA), although DNA adduct formation was similar in
both strains (Trempus et al, 2007). While the above studies suggest
that decreased regeneration rates affect cancer incidence, a great
deal remains to be done to substantiate this hypothesis.
CONCLUSION
Recent studies suggest that aspects of normal ageing may be caused
by decreased stem cell regenerative potential. This decrease in
regenerative potential may be the consequence of the unavoidable
accumulation of DNA damage and hyperactive growth factor
signalling, which in turn initiate tumour-suppressive mechanisms
designed to prevent uncontrolled cell proliferation. These mechanisms
include apoptotic and senescence programs regulated by tumour
suppressor genes, such as p16
INK4A, p53 and others. Thus, anti-
cancer mechanisms may contribute to decline in stem cell function
and may inadvertently promote affects that we know as ageing. If
cancer suppression and ageing are intimately linked, the question
arises whether it will be possible to promote tumour-suppressive
responses without leading to accelerated ageing. The recent study
by Matheu et al (2007) suggests that such treatments may be
possible so long as they selectively enhance responses to DNA
damage, rather than non-selectively inducing p53 in all cells and
causing inappropriate stem cell attrition. Other interventions to
combat cancer and ageing may include the prevention of DNA
damage (eg antioxidants), stem cell transplantation and regulation
of the self-renewal of existing stem cells. Of course, for such
interventions to be practical, additional studies will be necessary to
further confirm and explore the connections described herein
between stem cell exhaustion, tumour suppression and ageing.
ACKNOWLEDGEMENTS
We apologise to colleagues whose work could only be cited
indirectly. Financial support of YR and EJB is provided by the
National Institute on Aging (1R01AG027376-01) and the Abramson
Family Cancer Research Institute.
Tissue regenerative capacity
Time
Death
Death
A
g
e
i
n
g
C
a
n
c
e
r
DNA damage, hyperproliferation signals, other stress
Tumour
Healthy cell
capable of tissue
regeneration
Senescent/apoptotic
cell due to tumour
suppression
mechanisms
Transformed cell
that escaped
senescence
or apoptosis
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